Liraglutide Protects the Heart From Methotrexate Chemotherapy Damage

What the researchers found

Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and antioxidant pathway modulation, adding chemo-cardioprotection to GLP-1 benefits.

Why it matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The numbers in context

Four groups of rats tested. Methotrexate given as single dose of 20 mg/kg. Two different liraglutide doses evaluated for cardioprotection.

How the study worked

Study methodology detailed in the full publication.

Who was studied

Rats receiving methotrexate with or without liraglutide cardioprotection

What this study cannot tell us

Study limitations in the full publication.

How to read the evidence

Evidence level based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

Questions still open

• What are the long-term implications?
• How do results compare to other evidence?
• What further research is needed?

Common questions

Read the original research

Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.

Journal of biochemical and molecular toxicology, 39(12), e70606

Citation

Ali, Dina A; Ibrahim, Dalia; Kolieb, Eman; Abdel Fattah, Islam O; Maher, Shymaa A; Elkelish, Amr; Abdalneim, Nasir A; Abozied, Nadia. (2025). Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.. Journal of biochemical and molecular toxicology, 39(12), e70606. https://doi.org/10.1002/jbt.70606